Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling
Myrto Moutafi(University General Hospital Attikon), David L. Rimm(Yale University), Niki Gavrielatou(National and Kapodistrian University of Athens), Thazin Nwe Aung(Yale University), Prajan Divakar(Dartmouth College), Ioannis Vathiotis(Yale University), Aileen I. Fernandez(Yale University), Jon Zugazagoitia(Instituto de Salud Carlos III), Vesal Yaghoobi(Yale University), Sandra Martínez-Morilla(Yale University), Kurt A. Schalper(Yale University), Roy S. Herbst(Smilow Cancer Hospital)
Cited by 40
Related Papers
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k